iNCOVACC will be the world’s first COVID-19 booster dose. It will give India more options to choose from when it comes to third doses or precautionary doses
View More Bharat Biotech launches nasal vaccine iNCOVACC
A video of Chief Executive Officer of US-based pharma giant Pfizer Alberta Bourla dodged media’s queries on the efficacy of its Covid vaccine against transmission…
View More Pfizer CEO gets grilled at Davos; India stands vindicated for not buckling under pressure
Bharat Biotech’s Intranasal Vaccine receives both Primary series and Heterologous booster approval from from the Central Drugs Standard Control Organisation (CDSCO). This is first ever…
View More Bharat Biotech’s Covid nasal vaccine gets CDSCO approval
Bharat Biotech International Limited (BBIL) on Monday said that it has completed the phase III trials and booster doses for the Covaxin Intranasal Covid-19 vaccine.
View More Bharat Biotech Completes Phase III Trial Of Intranasal Covid Vaccine
KOLKATA: Japan has approved the booster shot of Covaxin, the anti-Covid vaccine developed by India’s Bharat Biotech, for travellers, the drug maker announced on Friday. “We…
View More Japan Approves Covaxin Booster Dose For Travellers
NEW DELHI: India’s Bharat Biotech, Switzerland’s ExcellGene SA and University of Sydney have come together to manufacture a “variant-proof” Covid-19 vaccine. The SARS-CoV-2 vaccine candidate…
View More Bharat Biotech Partners With 2 Others For ‘Variant-Proof’ Covid Vaccine
NEW DELHI: Bharat Biotech’s Covaxin has proven to be ‘safe, well-tolerated, and highly immunogenic’ in children in Phase II/III studies, the results of which are…
View More Covaxin Safe, Highly Immunogenic In Children, Says Study
NEW DELHI: The Drugs Controller General of India (DCGI) on Tuesday granted a restricted emergency use authorisation to Bharat Biotech’s Covaxin for children aged…
View More Bharat Biotech’s Covaxin Gets Nod For Restricted Emergency Use For Children Aged 6-12
NEW DELHI: In a major development that will boost the world’s fight against the COVID-19 virus, Hyderabad-based Bharat Biotech on Thursday announced that its…
View More Covaxin To Be Commercially Available In North America
NEW DELHI: Bharat Biotech International Limited confirms that COVAXIN successfully conducted the stage II/III study on children. The trials have proven to be safe, well…
View More ‘COVAXIN Shows Better Antibody Response In Children Aged Between 2-18 Years Than Adults’
Even as India celebrated the 100 Crore vaccine dose mark last week, Dr. Krishna Ella who is the founder of Bharat Biotech, maker of indegenious…
View More Medicos Laud India’s First Upcoming Nasal Vax; Admit Global R&D Still Required
NEW DELHI: In the part two of an extensive interview with The New Indian’s Executive Editor, Dr Krishna Ella of Bharat Biotech speaks on the…
View More We’re Producing 4-5 Cr Covaxin Doses Per Month, Plan To Ramp Up By 1.5 Cr: Bharat Biotech MD (Part 2)